Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Jun Sugisaka(Sendai Kousei Hospital), Yasushi Honda(National Institute for Environmental Studies), Kana Ono(Sendai Kousei Hospital), Tomoiki Aiba(Sendai Kousei Hospital), Keisuke Terayama(Sendai Kousei Hospital), Yosuke Kawashima(Sendai Kousei Hospital), Yutaka Domeki(Sendai Kousei Hospital), Shinsuke Yamanda(Sendai Kousei Hospital), Kyoji Tsurumi(Sendai Kousei Hospital), Mari Aso(Sendai Kousei Hospital), Takahiro Ogasawara(Sendai Kousei Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Sachiko Kawana(Sendai Kousei Hospital), Yuichiro Kimura(Tohoku University), Yukihiro Toi(Sendai Kousei Hospital), Atsushi Nakamura(Sendai Kousei Hospital), R. Saito(Sendai Kousei Hospital), Hisashi Shimizu
Cited by 4
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695